KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Non-Current Liabilities: 2017-2024

Historic Total Non-Current Liabilities for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $159.2 million.

  • Aquestive Therapeutics' Total Non-Current Liabilities rose 8.00% to $165.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.6 million, marking a year-over-year increase of 8.00%. This contributed to the annual value of $159.2 million for FY2024, which is 1.67% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Total Non-Current Liabilities of $159.2 million as of FY2024, which was down 1.67% from $161.9 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Total Non-Current Liabilities high stood at $173.6 million for FY2022, and its period low was $109.4 million during FY2020.
  • In the last 3 years, Aquestive Therapeutics' Total Non-Current Liabilities had a median value of $161.9 million in 2023 and averaged $164.9 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Total Non-Current Liabilities soared by 31.47% in 2020 and then declined by 6.74% in 2023.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Total Non-Current Liabilities stood at $109.4 million in 2020, then rose by 29.43% to $141.6 million in 2021, then rose by 22.56% to $173.6 million in 2022, then dropped by 6.74% to $161.9 million in 2023, then declined by 1.67% to $159.2 million in 2024.